title: Respiratory tract mucin genes and mucin glycoproteins in health and disease.
abstract: This review focuses on the role and regulation of mucin glycoproteins (mucins) in airway health and disease. Mucins are highly glycosylated macromolecules (> or =50% carbohydrate, wt/wt). MUC protein backbones are characterized by numerous tandem repeats that contain proline and are high in serine and/or threonine residues, the sites of O-glycosylation. Secretory and membrane-tethered mucins contribute to mucociliary defense, an innate immune defense system that protects the airways against pathogens and environmental toxins. Inflammatory/immune response mediators and the overproduction of mucus characterize chronic airway diseases: asthma, chronic obstructive pulmonary diseases (COPD), or cystic fibrosis (CF). Specific inflammatory/immune response mediators can activate mucin gene regulation and airway remodeling, including goblet cell hyperplasia (GCH). These processes sustain airway mucin overproduction and contribute to airway obstruction by mucus and therefore to the high morbidity and mortality associated with these diseases. Importantly, mucin overproduction and GCH, although linked, are not synonymous and may follow from different signaling and gene regulatory pathways. In section i, structure, expression, and localization of the 18 human MUC genes and MUC gene products having tandem repeat domains and the specificity and application of MUC-specific antibodies that identify mucin gene products in airway tissues, cells, and secretions are overviewed. Mucin overproduction in chronic airway diseases and secretory cell metaplasia in animal model systems are reviewed in section ii and addressed in disease-specific subsections on asthma, COPD, and CF. Information on regulation of mucin genes by inflammatory/immune response mediators is summarized in section iii. In section iv, deficiencies in understanding the functional roles of mucins at the molecular level are identified as areas for further investigations that will impact on airway health and disease. The underlying premise is that understanding the pathways and processes that lead to mucus overproduction in specific airway diseases will allow circumvention or amelioration of these processes.
authors.affiliation: Research Center for Genetic Medicine, Room 5700, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA. mrose@cnmc.org
authors.forename: Mary Callaghan
authors.initials: MC
authors.lastname: Rose
authors.forename: Judith A
authors.initials: JA
authors.lastname: Voynow
mesh_terms: D000818:Animals; D006023:Glycoproteins / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D008168:Lung / Q000378:metabolism; D009077:Mucins / Q000235:genetics* / Q000378:metabolism; D012137:Respiratory System / Q000378:metabolism*; D012140:Respiratory Tract Diseases / Q000235:genetics* / Q000378:metabolism*
chemical_list: D006023:Glycoproteins; D009077:Mucins